FFM

Fairmount Funds Management Portfolio holdings

AUM $1.31B
1-Year Est. Return 214.24%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+214.24%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$1.31B
AUM Growth
+$202M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
17
New
Increased
Reduced
Closed

Top Buys

1
+$17.3M
2
+$15.6M
3
+$12.5M
4
ZBIO
Zenas BioPharma
ZBIO
+$10.4M
5
IKT icon
Inhibikase Therapeutics
IKT
+$3.98M

Top Sells

1
+$99M
2
+$67.9M
3
+$60.6M
4
DNTH icon
Dianthus Therapeutics
DNTH
+$45.4M
5
ATXS
Astria Therapeutics
ATXS
+$25.9M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
1
Cogent Biosciences
COGT
$6.04B
$320M 24.34%
9,003,418
APGE icon
2
Apogee Therapeutics
APGE
$4.68B
$155M 11.77%
2,048,647
SYRE icon
3
Spyre Therapeutics
SYRE
$3.15B
$132M 10.02%
4,018,101
VRDN icon
4
Viridian Therapeutics
VRDN
$2.8B
$122M 9.27%
3,914,458
+454,545
ORKA
5
Oruka Therapeutics
ORKA
$1.59B
$112M 8.55%
3,705,262
DNTH icon
6
Dianthus Therapeutics
DNTH
$2.39B
$88.1M 6.7%
2,137,191
-1,170,000
ZBIO
7
Zenas BioPharma
ZBIO
$1.35B
$80.2M 6.11%
2,209,025
+316,219
NUVL icon
8
Nuvalent
NUVL
$7.78B
$73.2M 5.57%
727,563
JBIO
9
Jade Biosciences
JBIO
$686M
$70.3M 5.35%
4,553,494
+1,333,126
ELVN icon
10
Enliven Therapeutics
ELVN
$1.71B
$57.2M 4.35%
3,711,444
KNSA icon
11
Kiniksa Pharmaceuticals
KNSA
$3.44B
$54.4M 4.14%
1,319,688
-453,151
CBIO
12
Crescent Biopharma
CBIO
$341M
$32.6M 2.48%
2,747,866
+1,360,000
IKT icon
13
Inhibikase Therapeutics
IKT
$232M
$17.7M 1.35%
8,625,000
+2,500,000
ABVX
14
Abivax
ABVX
$8.78B
– –
-713,434
ATXS
15
DELISTED
Astria Therapeutics
ATXS
– –
-3,554,129
AXSM icon
16
Axsome Therapeutics
AXSM
$8.39B
– –
-815,176
SRRK icon
17
Scholar Rock
SRRK
$4.52B
– –
-1,824,031